Clinical trials: sponsored by University College, London
Blood Cancer
Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies
KCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell…
- Trial name
- KCAT19 (NCT05391490)
- Testing
- KCAT19 T cells
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University College, London
Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Not Having Achieved Remission
Determining the Mechanisms of Loss of CAR T Cell Persistence
A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells).
- Conditions
- Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, Adult
- Trial name
- CARPERS (NCT05809284)
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Sarcoma
Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma
MIGHTY is a multicentre, open label, phase 1 clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children, teenagers and young adults aged 1-24 with relapsed or refractory (r/r) rhabdomyosarcoma…
- Trial name
- MIGHTY (NCT07751380)
- Testing
- Biological/Vaccine: hBRCA84D CAR T cells
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- University College, London
Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
This is an open label, non-randomised, multicentre Phase I to determine the safety of tacrolimus-resistant autologous EBV-specific cytotoxic T-cells (EBV CTL) and compare their expansion/persistence with control EBV CTL in solid…
- Trial name
- ITREC (NCT03131934)
- Testing
- Autologous EBV-CTL transduced with vector SFG-CNA12, Autologous EBV-CTL transduced with control vector SFG-CNA8, Leucapheresis
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- University College, London
Cancer Survivors, Cardiotoxicity
In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors
The BREATHS trial aims to investigate whether overnight in-bedroom air filtration reduces inflammation and cardiac biomarkers in adult survivors of cancer who are at high risk for cardiovascular complications.
- Conditions
- Cancer Survivors, Cardiotoxicity, Cardiovascular Toxicity Induced by Antitumoral Drugs
- Trial name
- BREATHS (NCT06778122)
- Testing
- High efficiency particulate air filtration system (nightly administration), High efficiency particulate air filtration system (nightly and daily administration)
- Where
- 3 sites in Spain
- Volunteers
- 10 people
- Sponsor
- University College, London
Chronic Subdural Hematomas
Middle Meningeal Artery Coagulation During Burr-Hole Drainage for Chronic Subdural Haematoma (BURR-MMA)
Chronic subdural haematoma (cSDH) is a common condition in older adults, usually treated by burr-hole surgery to drain the collection.
- Trial name
- BURR-MMA (NCT07549893)
- Testing
- CT-Guided Intra-Operative Middle Meningeal Artery Interruption
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University College, London
Localised Prostate Cancer
BeSpoke Decision Support for Patients With Newly Diagnosed Localised Prostate Cancer
The goal of this randomised clinical trial is to assess whether personalised treatment counselling can improve the decision-making experience in patients with a new diagnosis of localised prostate cancer.
- Trial name
- BeSpoke (NCT07135271)
- Testing
- Bespoke Decision Support tool, Standard of Care (SOC) decision support material
- Where
- United Kingdom
- Volunteers
- 346 people
- Sponsor
- University College, London
Obsessive - Compulsive Disorder, Tic Disorder, Chronic Motor or Vocal
Integrating Exposure and Response Prevention and Habit Reversal Techniques to Treat a Tourettic Subtype of Obsessive-Compulsive Disorder (Tourettic OCD)
Obsessive-Compulsive Disorder and Tic Disorders frequently co-occur, and a subgroup of patients - those with a Tourettic Subtype of OCD (TOCD) - present with concurrent obsessive-compulsive and tic symptoms.
- Conditions
- Obsessive - Compulsive Disorder, Tic Disorder, Chronic Motor or Vocal, Tic Disorders, Tic Disorder, Combined Vocal and Multiple Motor
- Trial name
- TORCH (NCT07725926)
- Testing
- Exposure and Response Prevention (ERP), Habit Reversal Training (HbRT, Psychoeducation and Supportive Intervention
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- University College London Hospitals
Liver Cirrhosis
Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial
Liver disease is the only common cause of death that is increasing in numbers. Once people develop severe scarring (cirrhosis), there are no medications proven to help them live longer, healthier lives.
- Trial name
- APEACH (NCT07726693)
- Testing
- Apixaban 2.5 mg twice daily
- Volunteers
- 1,142 people
- Sponsor
- University College, London
Epilepsy
AI-enhanced LF-MRI in Epilepsy
The global burden of epilepsy is high affecting over 50 million people worldwide. Majority live in low- and middleincome countries (LMICs) where access to diagnosis and treatment is limited.
- Trial name
- ALF-ME (NCT07717632)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 39 people
- Sponsor
- University College, London
Alzheimer's Disease (AD), Mild Cognitive Impairment Due to Alzheimer's Disease
An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease
A multicentre, interventional, multi-arm, multi-stage Phase 3 trial including randomisation, double blinding, placebo control evaluation of treatments for sustained clinical response (18 months) in symptomatic Alzheimer's Disease…
- Conditions
- Alzheimer's Disease (AD), Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer Disease Dementia
- Trial name
- AD-SMART (NCT07724132)
- Testing
- Atomoxetine, Metformin 1000 mg Oral Tablet
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,200 people
- Sponsor
- University College, London
Cancer of Prostate, Cancer Head Neck
ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer
The aim of this study is to look at whether an Artificial Intelligence (AI) based computer program can automate two components of the radiotherapy treatment pathway to a sufficient quality standard to enable its routine clinical…
- Conditions
- Cancer of Prostate, Cancer Head Neck, Cancer Cervix
- Trial name
- NCT05653063
- Testing
- A web-based artificial intelligence (AI) auto-planning tool
- Where
- 6 sites in India, Jordan and 2 more
- Volunteers
- 1,029 people
- Sponsor
- University College, London
Anxiety, Depression
Evaluating Knowledge Insight Tools (KIT) for Reducing Anxiety and Low Mood in UK Secondary School Students
Background and Study Aims: Secondary school students are reporting unprecedented levels of anxiety and mood difficulties. To ensure that the needs of all young people are met, there is a need to evaluate more accessible forms of…
- Conditions
- Anxiety, Depression, Internalizing Problems, Low Mood
- Trial name
- NCT06188962
- Testing
- CBT-informed school-based counselling
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University College, London
MINS
PeriOperative Medicine - Metabolic Inflexibility as a Mechanism for Myocardial Injury After Non-Cardiac Surgery
The goal of this observational study is to learn whether metabolic inflexibility, which means reduced ability of the body to switch between using fats and sugars for energy, is associated with myocardial injury after non-cardiac…
- Trial name
- POM-MIMICS (NCT07694453)
- Testing
- Pre-operative Metabolic Inflexibility
- Volunteers
- 300 people
- Sponsor
- University College, London
Lung Cancer, Non-small Cell, Small Cell Lung Cancer
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.
- Conditions
- Lung Cancer, Non-small Cell, Small Cell Lung Cancer, Pleural Mesothelioma
- Trial name
- NCT05628376
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- University College, London
Hodgkin Lymphoma
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel.
- Trial name
- RADAR (NCT04685616)
- Testing
- Involved site radiotherapy, Doxorubicin, Bleomycin
- Where
- 72 sites in United States, Australia and 10 more
- Volunteers
- 1,042 people
- Sponsor
- University College, London
Proliferative Vitreoretinopathy
Imaging and Predictive Modelling of Proliferative Vitreoretinopathy.
Patients with retinal detachment are at risk of recurrence and failure of surgery requiring multiple surgeries due to a condition called proliferative vitreoretinopathy (PVR).
- Trial name
- NCT07682025
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University College, London
Prostate CA
Prostate MRI Analysis by Radiologists and Artificial Intelligence - Disease Identification and Guided Management
Prostate cancer is the most common male cancer in 112 countries and makes up 7% of global cancer cases, and is the second leading cause of cancer-related deaths in men.
- Trial name
- PARADIGM (NCT07647445)
- Testing
- AI (Lucida Pi) interpretation, Radiologist interpretation
- Volunteers
- 500 people
- Sponsor
- University College, London
Mantle Cell Lymphoma
Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma
This is a phase II, single-arm, open-label, multicentre study of acalabrutinib and rituximab for elderly or frail patients with previously untreated mantle cell lymphoma.
- Trial name
- CARAMEL (NCT05004064)
- Testing
- Acalabrutinib, Rituximab
- Where
- 12 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London
Respiratory Monitoring
Respiratory OBservation Using Ultra-Sensitive nanoTechnology
The Problem - About one in three patients get even more sick while they are in hospital. This often happens because of chest infections, sepsis (very serious infection), or heart problems.
- Trial name
- ROBUST (NCT07650539)
- Testing
- Nanotechnology respiratory monitor
- Where
- United Kingdom
- Volunteers
- 148 people
- Sponsor
- University College, London